Protaryx Medical completes first-in-human trial of transseptal puncture device
US-based Protaryx Medical has completed a first-in-human trial of its transseptal puncture (TSP) device. The company’s trial enrolled five patients,…
All articles by Ross Law
Ross Law
-
-
Albus demonstrates device’s ability to detect asthma attacks in children
UK-based Albus Health (formerly BreathOx) has shared data revealing that its Albus Home AI-powered monitoring device can detect warning signs…
-
Amgen speaks out about bone density concerns with obesity drug
Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s…
-
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials
AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of schizophrenia, failed to…
-
Customer-centricity takes spotlight during clinical transformation
Alcon decided to take a platform-based approach to support its clinical transformation efforts when parent company Novartis decided to spin…
-
Ondine accelerates pivotal antimicrobial trial after $11m financing
Ondine Biomedical will initiate a Phase III trial of its light-activated antimicrobial technology to reduce healthcare-associated infections (HAIs) early after…
-
Alloplex’s cancer immunotherapy shows promise in Phase I trial
Alloplex Biotherapeutics’ autologous SUPLEXA cell immunotherapy for cancer has demonstrated promise in a first-in-human study. In the Phase I trial,…
-
First participants dosed in trial of long-acting malaria preventative
Medicines for Malaria Venture (MMV) and Quotient Sciences have dosed the first participants in a trial of MMV371, a long-acting…
-
NIH launches precision medicine trial for myeloid cancers
The US National Institutes of Health (NIH) has launched a precision medicine trial that aims to match patients with myeloid…
-
Kezar Life Sciences discontinues lupus nephritis programme after fatalities
Clinical stage biopharma company Kezar Life Sciences is discontinuing its LN clinical programme following the death of four patients. In…